OBJECTIVES: Posaconazole is effective in preventing invasive fungal infections in neutropenic pediatric patients. The oral suspension has challenges in administration and absorption that are theorized to be minimized with delayed release tablets. However, this has not been validated in the pediatric population. This study was conducted to compare the efficacy and safety of posaconazole suspension and delayed release tablets in pediatric hematology/oncology patients. METHODS: A retrospective chart review in pediatric hematology/oncology patients was conducted from February 2013 to February 2017. Data collected include patient demographic data; posaconazole formulation, dose, and serum concentrations; and adverse events. RESULTS: Sixty-five patients with 353 serum posaconazole concentrations were included; 51.6% of concentrations drawn while patients were receiving posaconazole suspension were therapeutic, whereas 62.5% of concentrations drawn while patients were receiving posaconazole delayed release tablets were therapeutic (p = 0.035). Serum concentrations drawn while taking acid suppression (histamine receptor antagonists or proton pump inhibitors) and posaconazole suspension were less likely to be therapeutic (p < 0.0001) compared with those taken while receiving delayed release tablets. Adverse event profiles were similar between both formulations. CONCLUSIONS: Delayed release tablets proved more effective in achieving therapeutic serum posaconazole concentrations than posaconazole suspension, with minimal difference in adverse events, in pediatric hematology/oncology patients. Copyright Published by the Pediatric Pharmacy Association. All rights reserved. For permissions, mhelms@pediatricpharmacy.org 2020.
OBJECTIVES:Posaconazole is effective in preventing invasive fungal infections in neutropenic pediatricpatients. The oral suspension has challenges in administration and absorption that are theorized to be minimized with delayed release tablets. However, this has not been validated in the pediatric population. This study was conducted to compare the efficacy and safety of posaconazole suspension and delayed release tablets in pediatric hematology/oncology patients. METHODS: A retrospective chart review in pediatric hematology/oncology patients was conducted from February 2013 to February 2017. Data collected include patient demographic data; posaconazole formulation, dose, and serum concentrations; and adverse events. RESULTS: Sixty-five patients with 353 serum posaconazole concentrations were included; 51.6% of concentrations drawn while patients were receiving posaconazole suspension were therapeutic, whereas 62.5% of concentrations drawn while patients were receiving posaconazole delayed release tablets were therapeutic (p = 0.035). Serum concentrations drawn while taking acid suppression (histamine receptor antagonists or proton pump inhibitors) and posaconazole suspension were less likely to be therapeutic (p < 0.0001) compared with those taken while receiving delayed release tablets. Adverse event profiles were similar between both formulations. CONCLUSIONS: Delayed release tablets proved more effective in achieving therapeutic serum posaconazole concentrations than posaconazole suspension, with minimal difference in adverse events, in pediatric hematology/oncology patients. Copyright Published by the Pediatric Pharmacy Association. All rights reserved. For permissions, mhelms@pediatricpharmacy.org 2020.
Authors: Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Wendy M Kersemaekers; Peter Dogterom; Jialin Xu; Eugene E Marcantonio; Rik de Greef; Hetty Waskin; Marlou L P S van Iersel Journal: Antimicrob Agents Chemother Date: 2015-03-30 Impact factor: 5.191
Authors: Natasha N Pettit; Marisa H Miceli; Christina G Rivera; Prasanna P Narayanan; Anthony J Perissinotti; Meier Hsu; Jennifer Delacruz; Zivile Gedrimaite; Zhe Han; Jennifer Steinbeck; Jennifer Pisano; Susan K Seo; Alla Paskovaty Journal: J Antimicrob Chemother Date: 2017-08-01 Impact factor: 5.790
Authors: Michelle Science; Paula D Robinson; Tamara MacDonald; Shahrad Rod Rassekh; L Lee Dupuis; Lillian Sung Journal: Pediatr Blood Cancer Date: 2013-11-26 Impact factor: 3.167
Authors: M Döring; M Eikemeier; K M Cabanillas Stanchi; U Hartmann; M Ebinger; C-P Schwarze; A Schulz; R Handgretinger; I Müller Journal: Eur J Clin Microbiol Infect Dis Date: 2015-02-14 Impact factor: 3.267
Authors: M Döring; O Blume; S Haufe; U Hartmann; A Kimmig; C-P Schwarze; P Lang; R Handgretinger; I Müller Journal: Eur J Clin Microbiol Infect Dis Date: 2013-10-31 Impact factor: 3.267
Authors: Morgan Belling; Abraham S Kanate; Alexandra Shillingburg; Xiaoxiao Lu; Sijin Wen; Nilay Shah; Michael Craig; Aaron Cumpston Journal: Leuk Res Treatment Date: 2017-06-11
Authors: Julio Maquera-Afaray; Medalit Luna-Vilchez; Blanca Salazar-Mesones; Diana Portillo-Alvarez; Luis Uribe-Ramirez; Graciela Taipe-Sedano; Carlos Santillán-Salas; José W López Journal: J Pediatr Pharmacol Ther Date: 2021-12-22
Authors: Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia Journal: Antimicrob Agents Chemother Date: 2021-10-25 Impact factor: 5.938